Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma
Yonsei Medical Journal · 2024
DOI: 10.3349/ymj.2023.0263 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Yonsei Medical Journal, 2024. Verfasst von Hong Jun Lee und 10 weiteren Autor:innen. Beteiligte Einrichtung: Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Nivolumab, Carcinoma, Hepatocellular, Phenylurea Compounds, Pyridines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Yonsei University College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
- Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
- Yonsei Liver Center, Severance Hospital, Seoul, Korea.
- Department of Radiology and Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
- Yonsei Liver Center, Severance Hospital, Seoul, Korea. dyk1025@yuhs.ac.
ORCID-Profile: Hong Jun Lee, Jae Seung Lee, Hyesung So, Ja Kyung Yoon, Jin-Young Choi, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim
Zitieren
APA
Lee, H. J., Lee, J. S., So, H., Yoon, J. K., Choi, J. Y., Lee, H. W., Kim, B. K., Kim, S. U., Park, J. Y., Ahn, S. H., & Kim, D. Y. (2024). Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma. Yonsei Medical Journal. https://doi.org/10.3349/ymj.2023.0263
Vancouver
Lee HJ, Lee JS, So H, Yoon JK, Choi JY, Lee HW, et al. Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma. Yonsei Medical Journal. 2024. doi:10.3349/ymj.2023.0263
BibTeX
@article{Lee2024,
author = {Lee, Hong Jun and Lee, Jae Seung and So, Hyesung and Yoon, Ja Kyung and Choi, Jin-Young and Lee, Hye Won and Kim, Beom Kyung and Kim, Seung Up and Park, Jun Yong and Ahn, Sang Hoon and Kim, Do Young},
title = {Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma},
journal = {Yonsei Medical Journal},
year = {2024},
doi = {10.3349/ymj.2023.0263}
}
EUVIMED